NCT05888493 2026-04-17
LEDA
Novartis
Phase 3 Active not recruiting
Clinical Trials
19 trialsNCT03269669 2026-04-13
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06149286 2026-04-13
OLYMPIA-5
Regeneron Pharmaceuticals
Phase 3 Recruiting
NCT06191744 2026-04-13
EPCOREâ„¢FL-2
Genmab
Phase 3 Recruiting
NCT04542824 2026-04-08
EPCOREâ„¢ NHL-3
Genmab
Phase 1/2 Active not recruiting
NCT04663347 2026-04-08
EPCOREâ„¢ NHL-2
Genmab
Phase 1/2 Active not recruiting
NCT04903197 2026-04-01
Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma
Novartis
Phase 1 Terminated
NCT05025800 2026-03-20
ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT04246086 2026-03-19
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma
Hoffmann-La Roche
Phase 1/2 Active not recruiting
NCT05100862 2026-03-18
MAHOGANY
BeOne Medicines
Phase 3 Recruiting
NCT06313996 2026-03-18
A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3 Withdrawn
NCT02213913 2026-03-11
Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas
University of Chicago
Phase 1/2 Completed
NCT02446457 2026-03-09
Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05950165 2026-03-03
A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma
Cho Pharma Inc.
Phase 1/2 Recruiting
NCT04224493 2026-03-02
SYMPHONY-1
Ipsen
Phase 3 Recruiting
NCT07418190 2026-02-18
Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT04712097 2026-02-04
Celestimo
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT04669171 2026-01-30
SIDNEY
Enterome
Phase 1/2 Recruiting
NCT07355283 2026-01-27
IMM0306 in Combination With Lenalidomide vs Placebo in Combination With Lenalidomide in Patients With Relapsed/Refractory Follicular Lymphoma
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Phase 3 Not yet recruiting